Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Enterprise Therapeutics logo — Dedicated to the development of novel therapies to improve t...

Enterprise Therapeutics

Dedicated to the development of novel therapies to improve the lives of patients with respiratory disease

Founded 2014 United Kingdom Brighton, United Kingdom 13 employees Series B Total: $68.80M Health Care, Health and Wellness

General Information

Company Name Enterprise Therapeutics
Founded Year 2014
Location United Kingdom Brighton, United Kingdom
Founders / Decision Makers
Team member Team member
Employees 13
Industries Health Care, Health and Wellness
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Enterprise Therapeutics. To contact Enterprise Therapeutics, visit enterprisetherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Enterprise Therapeutics compare?

A PDF of Enterprise Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Enterprise Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Enterprise Therapeutics

Enterprise Therapeutics is a UK-based drug discovery company founded in 2014, dedicated to developing innovative therapies for respiratory diseases. The company's focus lies in addressing conditions such as cystic fibrosis, asthma, and COPD, where mucus congestion in the lungs severely impacts patients' breathing and quality of life. By targeting the underlying mechanisms of mucus congestion, Enterprise Therapeutics aims to reduce lung infections and improve patient well-being. The leadership team boasts extensive expertise in drug discovery, development, respiratory biology, and ion channel pharmacology, effectively positioning the company to pioneer advancements in this critical field. Its recent £26.00M Series B investment on January 29, 2024, attracted a notable consortium of investors including Novartis Venture Fund, Forbion, IP Group, Versant Ventures, Epidarex Capital, and Panakes Partners, underlining the industry's confidence in the company's potential. Additionally, its close collaboration with the School of Life Sciences at the University of Sussex further enhances its research capabilities and potential for groundbreaking discoveries in Health Care and Health and Wellness industries.

Business keywords: respiratory medicine, mucus congestion, COPD, asthma, cystic fibrosis, drug development, disease-modifying drugs, lung infections, quality of life, respiratory biology, ion channel pharmacology, University of Sussex, biopharmaceuticals

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Series B £26.00M 6
Novartis Venture Fund Forbion IP Group
Novartis Venture Fund, Forbion +4
29 Jan 2024
Grant £5.70M 1
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation
15 Oct 2019
Series B £29.00M 5
Novartis Venture Fund Forbion IP Group
Novartis Venture Fund, Forbion +3
12 Apr 2018
Grant £95.00K 1
Cystic Fibrosis Trust
05 Apr 2017
Venture Round £4.00M 2
Epidarex Capital
Epidarex Capital, Imperial Innovations
10 Nov 2016
Series A £2.40M 2
Epidarex Capital
Epidarex Capital, Imperial Innovations
21 May 2015
Series A £1.60M 1
Epidarex Capital
Epidarex Capital
16 Feb 2015

Latest News

View All
Fintech on the lead again - HSBC Innovation Banking and Dealroom's UK Innovation Update — Tech
Fintech on the lead again - HSBC Innovation Banking and Dealroom's UK Innovation Update
Tech Apr 17, 2024

Enterprise Therapeutics Alternatives & Competitors

Enterprise Therapeutics vs
Aer Therapeutics, Inc.
Aer Therapeutics, Inc. United States

Targeting mucus to improve lung health

Series A
11 employees
Biotechnology, Health Care
Enterprise Therapeutics vs
Monitored Therapeutics, Inc.
Monitored Therapeutics, Inc. United States

Solutions for Remote Patient Monitoring and Pharmaceutical Clinical Trials focused on Respiratory Di...

Venture round
27 employees
Health Care, Health and Wellness
Compare Enterprise Therapeutics vs Monitored Therapeutics, Inc.

FAQ About Enterprise Therapeutics

Dedicated to the development of novel therapies to improve the lives of patients with respiratory disease
Enterprise Therapeutics was founded in 2014.
Enterprise Therapeutics is headquartered in Brighton, United Kingdom.
Enterprise Therapeutics operates in Health Care and Health and Wellness. Its work centres on respiratory medicine, mucus congestion, COPD and asthma.
Enterprise Therapeutics has approximately 13 employees.
Enterprise Therapeutics has completed 7 funding rounds, raising a total of $68.80M. The latest funding stage is Series B.
Top alternatives and competitors to Enterprise Therapeutics include Aer Therapeutics, Inc., Monitored Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Enterprise Therapeutics and Aer Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Enterprise Therapeutics, https://bouncewatch.com/company/enterprise-therapeutics, updated 3 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout